Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia

Table 2 Cost-effectiveness of antibiotics for treatment of cSSSI patients

Treatment strategy	Total cost (USD)	Incremental cost (USD)	Total LY	LY saved^a	ICER per LY saved
Vancomycin	15,254		7.52
SXT/rifampicin	13,419	-1836	7.68	0.16	Dominant
Linezolid	16,387	1133	7.92	0.40	2833
Tedizolid	17,353	2099	7.90	0.38	5523
Daptomycin	17,238	1984	7.84	0.32	6200
Ceftaroline	17,971	2717	7.82	0.30	9057

cSSSI complicated skin and soft structure infection, USD US dollar, LY life-years, ICER incremental cost-effectiveness ratio, SXT trimethoprim/sulfamethoxazole
^aCalculated as the average cost per patient and the average number of LY per patient in this strategy minus those of the treatment of vancomycin

ISSN: 2047-2994